| Page 6 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Author(s): 
Garelius HKG, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, Mittelmann M, Stauder R, Čermák J, Sanz G, Langemeijer S, Malcovati L, Germing U, Sanhes L, d'Aveni M, Culligan D, Kotsianidis I, Koinig KA, van Marrewijk C, Crouch S, deWitte T, Smith A
Primary Author: 
Garelius HKG
Journal Title: 
Lancet Haematology
Original Publication Date: 
Feb 2025

Background: In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk

Bone Marrow Disease(s):